NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET
|
BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...
Eagle Hill School First to Use RxAir® UV Light Air Purifiers Campus-Wide to Combat Airborne Viruses
October 13, 2020 08:00 ET
|
Vystar Corp.
RxAir® UV-C Light inactivates 99.9% of airborne viruses, bacteria, mold & fungiTeachers more comfortable teaching in-person with RxAir in useVystar offering discounts to education institutions for...
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
September 03, 2020 21:42 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
Independent Studies Confirm Low Levels of Immune System Protein, Gelsolin, Associated with COVID-19 Severity
August 17, 2020 10:57 ET
|
BioAegis Therapeutics
BioAegis Conducting COVID-19 Clinical Trial of Gelsolin Therapeutic MORRISTOWN, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing...
Summit Academy Embraces Science of RxAir UV Light Air Purifiers to Reduce COVID-19 Risk
August 11, 2020 09:00 ET
|
Vystar Corp.
Worcester, MA, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Savvy administrators at Summit Academy in Worcester, Mass., are looking to science to help prevent COVID-19 infection as they enter the new school...
BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
August 05, 2020 18:16 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
July 15, 2020 13:34 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...
BioAegis Therapeutics Completes Over-Subscribed Financing for COVID-19 Trial
June 23, 2020 17:21 ET
|
BioAegis Therapeutics
MORRISTOWN, N.J., June 23, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical-stage private company focused on developing therapies for infectious, inflammatory and degenerative...
Kiniksa Announces Lancet Rheumatology Publication of Clinical Outcomes with Mavrilimumab in COVID-19
June 17, 2020 08:00 ET
|
Kiniksa Pharmaceuticals, Ltd.
HAMILTON, Bermuda, June 17, 2020 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company focused on discovering, acquiring, developing and...